RELMADA THERAPEUTICS, INC. SEC filings

Filings

1. 4RELMADA THERAPEUTICS, INC.RLMDSep 11

   2 insider filings

   Sergio Traversa, insider filing for RLMD

   Show all 2

   • 4Insider filing for RLMDSep 11
   • 4Insider filing for RLMDSep 11

   Sergio Traversa, reporting

2. 8-KRELMADA THERAPEUTICS, INC.RLMDSep 8

   Current report

3. SCHEDULE 13G/ARELMADA THERAPEUTICS, INC.RLMDAug 14

   Ownership stake disclosure by Squadron Capital Management LLC (amended)

   Squadron Capital Management LLC, filed by

4. 8-KRELMADA THERAPEUTICS, INC.RLMDAug 6

   Current report

5. 10-QRELMADA THERAPEUTICS, INC.RLMDAug 6

   Quarterly report

6. SCHEDULE 13GRELMADA THERAPEUTICS, INC.RLMDJul 29

   Ownership stake disclosure by BlackRock, Inc.

   BlackRock, Inc., filed by

7. 8-KRELMADA THERAPEUTICS, INC.RLMDJul 28

   Current report

8. SCHEDULE 13GRELMADA THERAPEUTICS, INC.RLMDJun 22

   Ownership stake disclosure by MILLENNIUM MANAGEMENT LLC

   MILLENNIUM MANAGEMENT LLC, filed by

9. S-8RELMADA THERAPEUTICS, INC.RLMDJun 18

   Employee stock plan registration

10. SCHEDULE 13GRELMADA THERAPEUTICS, INC.RLMDJun 9

    Ownership stake disclosure by Venrock Healthcare Capital Partners III, L.P.

    Venrock Healthcare Capital Partners III, L.P., filed by

11. 8-KRELMADA THERAPEUTICS, INC.RLMDMay 28

    Current report

12. S-3ASRRELMADA THERAPEUTICS, INC.RLMDMay 13

    Securities offering

13. SCHEDULE 13G/ARELMADA THERAPEUTICS, INC.RLMDMay 13

    Ownership stake disclosure by Adage Capital Management, L.P. (amended)

    Adage Capital Management, L.P., filed by

14. 8-KRELMADA THERAPEUTICS, INC.RLMDMay 12

    Current report

15. 10-QRELMADA THERAPEUTICS, INC.RLMDMay 12

    Quarterly report

16. SCHEDULE 13GRELMADA THERAPEUTICS, INC.RLMDMay 4

    Ownership stake disclosure by Commodore Capital LP

    Commodore Capital LP, filed by

17. DEFA14ARELMADA THERAPEUTICS, INC.RLMDApr 17

    Additional proxy materials

18. DEF 14ARELMADA THERAPEUTICS, INC.RLMDApr 17

    Proxy statement

19. EFFECTRELMADA THERAPEUTICS, INC.RLMDApr 10

    Registration declared effective

20. 424B3RELMADA THERAPEUTICS, INC.RLMDApr 9

    Securities offering

21. PRE 14ARELMADA THERAPEUTICS, INC.RLMDApr 6

    Preliminary proxy statement

22. S-3RELMADA THERAPEUTICS, INC.RLMDApr 3

    Securities offering

23. 8-KRELMADA THERAPEUTICS, INC.RLMDMar 20

    Current report

24. 10-KRELMADA THERAPEUTICS, INC.RLMDMar 19

    Annual report

25. 8-KRELMADA THERAPEUTICS, INC.RLMDMar 9

    Current report

26. SCHEDULE 13G/ARELMADA THERAPEUTICS, INC.RLMDFeb 17

    Ownership stake disclosure by Squadron Capital Management LLC (amended)

    Squadron Capital Management LLC, filed by

27. SCHEDULE 13GRELMADA THERAPEUTICS, INC.RLMDFeb 17

    Ownership stake disclosure by Spruce Street Capital LP

    Spruce Street Capital LP, filed by

28. SCHEDULE 13GRELMADA THERAPEUTICS, INC.RLMDFeb 12

    Ownership stake disclosure by Adage Capital Management, L.P.

    Adage Capital Management, L.P., filed by

29. SCHEDULE 13GRELMADA THERAPEUTICS, INC.RLMDFeb 6

    Ownership stake disclosure by JANUS HENDERSON GROUP PLC

    JANUS HENDERSON GROUP PLC, filed by

30. 424B5RELMADA THERAPEUTICS, INC.RLMDJan 30

    Securities offering

31. 4RELMADA THERAPEUTICS, INC.RLMDDec 16, 2025

    7 insider filings

    Chuck Ence, insider filing for RLMD

    Show all 7

    • 4Insider filing for RLMDDec 16, 2025
    • 4Insider filing for RLMDDec 16, 2025
    • 4Insider filing for RLMDDec 16, 2025
    • 4Insider filing for RLMDDec 16, 2025
    • 4Insider filing for RLMDDec 16, 2025
    • 4Insider filing for RLMDDec 16, 2025
    • 4Insider filing for RLMDDec 16, 2025

    Chuck Ence, reporting

32. 8-KRELMADA THERAPEUTICS, INC.RLMDDec 15, 2025

    Current report

33. SCHEDULE 13GRELMADA THERAPEUTICS, INC.RLMDNov 14, 2025

    Ikarian Capital, LLC has filed a Schedule 13G with the SEC, disclosing a 5.1% passive stake in Relmada Therapeutics, Inc. (RLMD). This filing indicates Ikarian Capital has acquired a significant minority position in the biopharmaceutical company, which is developing novel…

    Ikarian Capital, LLC, filed by

34. 8-KRELMADA THERAPEUTICS, INC.RLMDNov 13, 2025

    Relmada Therapeutics, Inc. (RLMD) announced the resignation of its Chief Executive Officer, effective immediately. This unexpected leadership change could significantly impact the company's strategic direction and ongoing clinical development programs, which are critical to…

35. 10-QRELMADA THERAPEUTICS, INC.RLMDNov 13, 2025

    Relmada Therapeutics, Inc. (RLMD) has filed its Q3 2025 quarterly report (Form 10-Q), providing investors with an update on the company's financial performance and operational activities during the period.

36. 4RELMADA THERAPEUTICS, INC.RLMDNov 6, 2025

    4 insider filings

    Chuck Ence, insider filing for RLMD

    Show all 4

    • 4Insider filing for RLMDNov 6, 2025
    • 4Insider filing for RLMDNov 6, 2025
    • 4Insider filing for RLMDNov 6, 2025
    • 4Insider filing for RLMDNov 6, 2025

    Chuck Ence, reporting

37. 8-KRELMADA THERAPEUTICS, INC.RLMDNov 5, 2025

    Current report

38. 424B5RELMADA THERAPEUTICS, INC.RLMDNov 5, 2025

    Securities offering

39. FWPRELMADA THERAPEUTICS, INC.Nov 4, 2025

    Securities offering

40. 8-KRELMADA THERAPEUTICS, INC.Nov 4, 2025

    Current report

Older filings on EDGAR